Limited studies have shown an association between the methyl-CpG-binding protein2 (MeCp2) genetic polymorphisms and systemic lupus erythematosus (SLE) in different populations, but the results are inconclusive. In order to get a precise and systematic estimation, a meta-analysis was performed.
Methods
A systematic literature search using English and Chinese databases (PubMed/Medline, Web of Knowledge, Wanfang Data (Chinese), etc.) for the eligible studies was performed. Based on heterogeneity among studies, random- or fixed-effects models were selected to analyze the risk of SLE associated with single-nucleotide polymorphisms (SNPs) of MeCP2 genetic polymorphisms.
Results
A significant increased risk of both SNPs of MeCP2 genetic variances associated with SLE was found. Analysis using a fixed-effects model found an increased risk of SLE with the A allele of rs2075596 (OR = 1.41, 95% CI: 1.34 to 1.49, p < 0.001), and the random-effects model also identified a risk factor of A allele of rs2239464 (OR = 1.31, 95% CI: 1.15 to 1.49, p = 0.001). Subgroup analysis and sensitivity analysis suggested that the major source of between-study heterogeneity stemmed from the difference between diverse ethnic groups. After omitting the smallest study, no publication bias was found, which further confirmed the reliability and stability of the meta-analysis.
Conclusions
Mutations of SNPs (rs2075596, rs2239464) of MeCP2 showed increased risk of developing SLE. Large-scale multicenter epidemiological studies in selected populations with other risk factors are urgently required.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
4.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
5.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
6.
Osio-SalidoEManapat-ReyesH. Epidemiology of systemic lupus erythematosus in Asia. Lupus2010; 19: 1365–1373.
7.
MokC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. Lupus2011; 20: 767–771.
8.
WakelandEKLiuKGrahamRRBehrensTW. Delineating the genetic basis of systemic lupus erythematosus. Immunity2001; 15: 397–408.
9.
BorchersATNaguwaSMShoenfeldYGershwinME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev2010; 9: 277–287.
10.
JakesRWBaeSCLouthrenooWMokCCNavarraSVKwonN. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken)2012; 64: 159–168.
11.
KeshetILieman-HurwitzJCedarH. DNA methylation affects the formation of active chromatin. Cell1986; 44: 535–543.
12.
BhakatKKMitraS. CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis2003; 24: 1337–1345.
13.
NanXCampoyFJBirdA. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell1997; 88: 471–481.
14.
JonesPLVeenstraGJWadePA. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet1998; 19: 187–191.
15.
NanXNgHHJohnsonCA. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature1998; 393: 386–389.
16.
SekigawaIOkadaMOgasawaraHKanekoHHishikawaTHashimotoH. DNA methylation in systemic lupus erythematosus. Lupus2003; 12: 79–85.
17.
SekigawaIKawasakiMOgasawaraH. DNA methylation: Its contribution to systemic lupus erythematosus. Clin Exp Med2006; 6: 99–106.
18.
SawalhaAHWebbRHanS. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One2008; 3: e1727–e1727.
19.
ChahrourMJungSYShawC. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science2008; 320: 1224–1229.
20.
RichardsonBScheinbartLStrahlerJGrossLHanashSJohnsonM. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum2005; 33: 1665–1673.
21.
JavierreBMFernandezAFRichterJ. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res2010; 20: 170–179.
22.
WenZXuWXuL. DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford)2007; 46: 1796–1803.
23.
LeiWLuoYYanK. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol2009; 38: 369–374.
24.
RenJPengCChenS. Association of methyl-CpG-binding protein 2 (MeCP2) polymorphisms with systemic lupus erythematosus (SLE) among Chinese Han population in south of the Yangtze River. Fudan University Journal of Medical Sciences2012; 39: 146–151.
25.
KaufmanKMZhaoJKellyJA. Fine mapping of Xq28: Both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis2013; 72: 437–444.
26.
HunterJESchmidtFLJacksonGB. Meta-analysis: Cumulating research findings across studies, Beverly Hills, CA: SAGE Publications, Inc, 1982.
27.
HigginsJThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med2002; 21: 1539–1558.
28.
Huedo-MedinaTBSánchez-MecaJMarín-MartínezFBotellaJ. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods2006; 11: 193–206.
29.
HedgesLVVeveaJL. Fixed- and random-effects models in meta-analysis. Psychol Methods1998; 3: 486–504.
30.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics1994; 50: 1088–1101.
31.
EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ1997; 315: 629–634.
32.
HigginsJThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ2003; 327: 557–560.
33.
TiffinNAdeyemoAOkpechiI. A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J Rare Dis2013; 8: 1–8.
34.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358: 929–939.
35.
NamjouBKothariPHKellyJA. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun2011; 12: 270–279.
36.
MunozLvan BavelCFranzSBerdenJHerrmannMvan der VlagJ. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus2008; 17: 371–375.
37.
ZhangYZhaoMSawalhaAHRichardsonBLuQ. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun2013; 41: 92–99.
38.
ZhouYQiuXLuoY. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus2011; 20: 1365–1371.
39.
AttwoodJYungRRichardsonB. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci2002; 59: 241–257.
40.
RobertsonKD. DNA methylation and human disease. Nat Rev Genet2005; 6: 597–610.
41.
LuoYLiYSuY. Abnormal DNA methylation in T cells from patients with subacute cutaneous lupus erythematosus. Br J Dermatol2008; 159: 827–833.
42.
HardyJSingletonA. Genomewide association studies and human disease. N Engl J Med2009; 360: 1759–1768.
43.
RischNMerikangasK. The future of genetic studies of complex human diseases. Science1996; 273: 1516–1517.
44.
LeiWLuoYLeiW. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol2009; 38: 369–374.
45.
OelkeKLuQRichardsonD. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum2004; 50: 1850–1860.
46.
DengCKaplanMJYangJ. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum2001; 44: 397–407.
47.
SestakALFürnrohrBGHarleyJBMerrillJTNamjouB. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis2011; 70(Suppl 1)i37–i43.
48.
Webb R, Wren JD, Jeffries M, et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis & Rheumatism 2009; 60: 1076–1084.
